破发股仁度生物某股东拟询价转让 上市即巅峰募7.3亿

Group 1 - The major shareholder CENTRAL CHIEF LIMITED plans to transfer 500,000 shares of Rendu Biotech, accounting for 1.25% of the total share capital, due to its own funding needs [1] - As of May 6, 2025, CENTRAL CHIEF LIMITED holds 2,497,691 shares, representing 6.24% of the total share capital, and is not a controlling shareholder or senior management of Rendu Biotech [1] - The transfer price will not be lower than 70% of the average trading price over the last 20 trading days prior to the invitation date [1] Group 2 - Rendu Biotech was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on March 30, 2022, with an initial offering price of 72.65 CNY per share [2] - The company raised a total of 726.5 million CNY, with a net amount of 652.76 million CNY after deducting issuance costs, which was 47.75 million CNY less than originally planned [2] - The funds were intended for the development of precision diagnostic reagents and smart device industrialization, as well as marketing network construction [2] Group 3 - The controlling shareholder and actual controller of Rendu Biotech is Jingliang Ju, who has a background in various companies in the United States and has been the chairman and chief scientist since 2007 [3]